Dr. Anna ME Bruynzeel

Amsterdam UMC (formerly VUmc)

Since 2012 Anna ME Bruynzeel is Radiation Oncologist at the VU University Medical Center Amsterdam, the Netherlands. Her areas of interest are Neuro-Oncology, Gastrointestinal tract Oncology, Stereotactic Ablative Radiotherapy and MR-guided Radiotherapy. The latter has recently been introduced in clinical practice using the MRIdian system. Anna belongs to the core team developing protocols and performing MR- guided adaptive treatment including patients with locally advanced pancreatic tumors, prostate cancer and kidney cancer.

dont miss

MR Guided Adaptive Radiation Therapy; three years of clinical experience at VUmc

MR-guided radiation therapy (MRgRT) is a novel and rapidly expanding treatment approach which has been clinically implemented at VUmc Amsterdam since early 2016. In addition to MR-based setup, it offers the potential for real-time target tracking during treatment, marker-less gated delivery, and if indicated, plan re-optimization to generate an optimal ´plan of the day’ for each fraction. MRgRT workflow, benefits, limitations, indications as well as early clinical results will be presented.

EVEN MORE SEMINARS

  • Hamed Javan MD: Speaking at the Oncology Convention

    Hamed Javan MD
    Jewish General Hospital

    Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

  • Dr. Anna ME Bruynzeel: Speaking at the Oncology Convention

    Dr. Anna ME Bruynzeel
    Amsterdam UMC (formerly VUmc)

    MR Guided Adaptive Radiation Therapy; three years of clinical experience at VUmc

  • Corina van den Hurk: Speaking at the Oncology Convention

    Corina van den Hurk
    Netherlands Comprehensive Cancer Organisation

    Hair loss through chemotherapy is not inevitable!

  • Professor Sun Myint: Speaking at the Oncology Convention

    Professor Sun Myint
    Clatterbridge Cancer Centre (Private Clinic)

    Rectal cancer- Do patients have a choice?

  • Khurum Khan: Speaking at the Oncology Convention

    Khurum Khan
    Royal Marsden NHS Foundation Trust

    Biomarkers of response and/or resistance to targeted therapies in refractory mCRC